Kodiak Sciences
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kodiak Sciences sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Kodiak Sciences: 11 sponsored US clinical trials, 2 recruiting.
Kodiak Sciences sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 9 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Macular Edema Secondary to Inflammation, with 2 trials.
Top-decile sponsor footprint
Kodiak Sciences ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
11 total, page 1 of 1
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
NCT06270836
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
NCT05066230
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
NCT04964089
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04603937
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04611152
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
NCT04592419
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
NCT04049266
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
NCT03790852
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 9 |
Therapeutic Areas
Where Kodiak Sciences enrollment is open (later-stage tilt)
2 recruiting of 11 indexed (18% open); 2 completed (18%).
Phase mix: 9 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Macular Edema Secondary to Inflammation (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kodiak Sciences: open-pipeline peers nationwide
Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Kodiak Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 trials (± recruiting share)
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Burke Medical Research Institute · 18% recruiting · 11 trials
- Grand Valley State University · 18% recruiting · 11 trials
- Imunon · 18% recruiting · 11 trials
- InventisBio Co. · 18% recruiting · 11 trials
Related
What to do with this Kodiak Sciences page
11 registered trials is a research-attention snapshot, not an endorsement of Kodiak Sciences or any single study.
- 2 of Kodiak Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Macular Edema Secondary to Inflammation is the condition Kodiak Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Macular Edema Secondary to Inflammation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kodiak Sciences pipeline card: 11 registered trials from official public datasets.Report a data error.